IPPRITT Main Scope

Last Update: 29/08/2019

Only publications directly related to the scope of the unit are reported here. Other publications are reported here.

  1. Natural killer cell infiltration is discriminative for antibody-mediated rejection and predicts outcome after kidney transplantation, Yazdani, S.; Callemeyn, J.; Gazut, S.; Lerut, E.; de Loor, H.; Wevers, M.; Heylen, L.; Saison, C., et al., Kidney International 2019, 95, 188-198 , http://doi.org/10.1016/j.kint.2018.08.027
  2. Development and validation of a peripheral blood mrna assay for the assessment of antibody-mediated kidney allograft rejection: A multicentre, prospective study, Van Loon, E.; Gazut, S.; Yazdani, S.; Lerut, E.; de Loor, H.; Coemans, M.; Noël, L.-H.; Thorrez, L., et al., EBioMedicine 2019,< /b> 46, 463-472, http://doi.org/10.1016/j.ebiom.2019.07.028
  3. Metabolic alterations of uterine grafts after extended cold ischemic storage: Experimental study in ewes, Tholance, Y.; Tricard, J.; Chianea, T.; Marquet, P.; Ponsonnard, S.; Sturtz, F.; Piccardo, A.; Gauthier, T., Molecular Human Reproduction 2019, http://doi.org/10.1093/molehr/gaz041
  4. Uterus transplantation in transgenders: Will it happen one day?, Tardieu, A.; Sallée, C.; Dion, L.; Piver, P.; Lavoué, V.; Gauthier, T.; CNGOF, C. D. é. d. l. T. U. e. F. C. d., Journal of Gynecology Obstetrics and Human Reproduction 2019, 48, 5-6, http://doi.org/10.1016/j.jogoh.2018.11.009
  5. The key role of warm and cold ischemia in uterus transplantation: A review, Tardieu, A.; Dion, L.; Lavoué, V.; Chazelas, P.; Marquet, P.; Piver, P.; Sallée, C.; Aubard, Y., et al., Journal of Clinical Medicine 2019, 8, http://doi.org/1 0.3390/jcm8060760
  6. Uterus transplantation: Questions and future prospects, Tardieu, A.; Dion, L.; Collinet, P.; Ayoubi, J. M.; Garbin, O.; Agostini, A.; Aubard, Y.; Piver, P., et al., Journal of Gynecology Obstetrics and Human Reproduction 2019, 48, 1-3, http://doi.org/10.1016/j.jogoh.2018.11.011
  7. Uterus transplantation: Which indications?, Tardieu, A.; Dion, L.; Collinet, P.; Ayoubi, J. M.; Garbin, O.; Agostini, A.; Aubard, Y.; Piver, P., et al., Journal of Gynecology Obstetrics and Human Reproduction 2019, 48, 7-8, ht tp://doi.org/10.1016/j.jogoh.2018.10.003
  8. Changes in the metabolic composition of storage solution with prolonged cold ischemia of the uterus, Tardieu, A.; Chazelas, P.; Faye, P.-A.; Favreau, F.; Nadal-Desbarats, L.; Sallée, C.; Margueritte, F.; Couquet, C.-Y., et al., Journal of Assisted Reproduction and Genetics 2019, 36< /i>, 1169-1178, http://doi.org/10.1007/s10815-019-01477-y
  9. A prognostic tool for individualized prediction of graft failure risk within ten years after kidney transplantation, Stamenic, D.; Rousseau, A.; Essig, M.; Gatault, P.; Buchler, M.; Filloux, M.; Marquet, P.; Prémaud, A., Journal of Transplantation 2019, 2019, 7245142, http://doi.org/10.1155/2019/7245142
  10. Nitrone-trolox conjugate as an inhibitor of lipid oxidation: Towards synergistic antioxidant effects, Socrier, L.; Rosselin, M.; Gomez Giraldo, A. M.; Chantemargue, B.; Di Meo, F.; Trouillas, P.; Durand, G.; Morandat, S., Biochimica Et Biophysica Acta. Biomembranes 2019, 1861, 1489-150 1, http://doi.org/10.1016/j.bbamem.2019.06.008
  11. Why dose adjust systemic exposure when looking for associations with adverse events in tacrolimus-treated transplant recipients?, Robertsen, I.; Woillard, J.-B.; Åsberg, A., British Journal of Clinical Pharmacology 2019, http://doi.org/10.1111/bcp.13 984
  12. Identification of factors affecting tacrolimus trough levels in latin american pediatric liver transplant patients, Riva, N.; Woillard, J.-B.; Distefano, M.; Moragas, M.; Dip, M.; Halac, E.; Cáceres Guido, P.; Licciardone, N., et al., Liver Transplantation: Official Publication of the American As sociation for the Study of Liver Diseases and the International Liver Transplantation Society 2019, 25, 1397-1407, http://doi.org/10.1002/lt.25495
  13. Population pharmacokinetic model and bayesian estimator for 2 tacrolimus formulations in adult liver transplant patients, Riff, C.; Debord, J.; Monchaud, C.; Marquet, P.; Woillard, J.-B., British Journal of Clinical Pharmacology 2019, 85, 1740-1750, http://doi.org/10.1111/bcp.13960
  14. Hepatitis b virus reactivation in transplant patients treated for hepatitis c recurrence: Prophylaxis makes the difference, Mouna, L.; Rossignol, E.; Tateo, M.; Coilly, A.; Duclos-Vallée, J.-C.; Duvoux, C.; Durand, F.; Tran, A., et al., Journal of Hepatology 2019, 70, 1297-1300, http://doi.org/10.1016/j.jhep.2019.02.019
  15. Pharmacodynamic monitoring of mtor inhibitors, Millán, O.; Wieland, E.; Marquet, P.; Brunet, M., Therapeutic Drug Monitoring 2019, 41, 160-167, http://doi.org/10.1097/FTD.0000000000000616
  16. Organizing a uterus transplantation programme: The designation of uterus transplantation centres in france, Lavoué, V.; Dion, L.; Tardieu, A.; Garbin, O.; Ayoubi, J. M.; Agostini, A.; Collinet, P.; Piver, P., et al., Journal of Gynecology Obstetrics and Human Reproduction 2019, 48, 15-18, http://doi.org/10.1016/j.jogoh.2018.09.010
  17. Successful control of hidradenitis suppurativa with verapamil: A case report, Laroche, M.-L.; Teste, M.; Vanoost, J.; Geniaux, H., Fundamental & Clinical Pharmacology 2019, 33, 122-124, http://doi.org/10.1111/fcp.12403
  18. Pharmacokinetics of prolonged-release once-daily formulations of tacrolimus in de novo kidney transplant recipients: A randomized, parallel-group, open-label, multicenter study, Kamar, N.; Cassuto, E.; Piotti, G.; Govoni, M.; Ciurlia, G.; Geraci, S.; Poli, G.; Nicolini, G., et al., Advances in Th erapy 2019, 36, 462-477, http://doi.org/10.1007/s12325-018-0855-1
  19. Therapeutic drug monitoring of everolimus in oncology: Evidences and perspectives, Falkowski, S.; Woillard, J.-B., Therapeutic Drug Monitoring 2019, http://doi.org/10.1097/FTD.0000000000000628
  20. Uterus transplantation: Where do we stand in 2018?, Dion, L.; Tardieu, A.; Piver, P.; Aubard, Y.; Ayoubi, J. M.; Garbin, O.; Agostini, A.; Collinet, P., et al., Journal of Gynecology Obstetrics and Human Reproduction 2019, 48, 11-13, http://doi.org/10.1016/j.jogoh.2018.09.008
  21. Uterus transplantation and altruistic surrogacy: Are they complementary or alternative options?-a statement from the cngof french uterus transplantation committee, Dion, L.; Tardieu, A.; Collinet, P.; Garbin, O.; Ayoubi, J. M.; Agostini, A.; Piver, P.; Aubard, Y., et al., Journal of Gynecology Ob stetrics and Human Reproduction 2019, 48, 293-295, http://doi.org/10.1016/j.jogoh.2019.02.001
  22. Measurement of glomerular filtration rate using a reference method, Chardon, L.; Dubourg, L.; Barin-Le Guellec, C.; Guinard, F.; Hannedouche, T.; Halimi, J.-M.; Mariat, C., Annales De Biologie Clinique 2019, 77, 371-374, http://doi.org/10. 1684/abc.2019.1455
  23. Sum of peak intensities outperforms peak area integration in itraq protein expression measurement by lc-ms/ms using a tripletof 5600+ platform, Burat, B.; Gonzalez, J.; Sauvage, F.-L.; Aouad, H.; Arnion, H.; Pinault, E.; Marquet, P.; Essig, M., Bioscience Reports 2019, 39, http://doi.org/10.1042/BSR20190904
  24. Cyclosporine a inhibits mrtf-srf signalling through na+/k+ atpase inhibition & actin remodelling, Burat, B.; Faucher, Q.; Čechová, P.; Arnion, H.; Di Meo, F.; Sauvage, F.-L.; Marquet, P.; Essig, M., FASEB BioAdvances 2019, 0 (ja), htt p://doi.org/10.1096/fba.2019-00027
  25. Therapeutic drug monitoring of tacrolimus-personalized therapy: Second consensus report, Brunet, M.; van Gelder, T.; Åsberg, A.; Haufroid, V.; Hesselink, D. A.; Langman, L.; Lemaitre, F.; Marquet, P., et al., Therapeutic Drug Monitoring 2019, 41, 261-307, http://doi.org/10.1097/FTD.0000000000000640
  26. Multidrug resistance-associated protein 4 in pharmacology: Overview of its contribution to pharmacokinetics, pharmacodynamics and pharmacogenetics, Berthier, J.; Arnion, H.; Saint-Marcoux, F.; Picard, N., Life Sciences 2019, 231, 116540, http://doi.org/10.1016/j.lfs.2019.06.015
  27. Big data in pharmacogenomics: Current applications, perspectives and pitfalls, Barrot, C.-C.; Woillard, J.-B.; Picard, N., Pharmacogenomics 2019, 20, 609-620, http://doi.org/10.2217/pgs-2018-0184
  1. Pharmacokinetic models to assist the prescriber in choosing the best tacrolimus dose, Woillard, J.-B.; Saint-Marcoux, F.; Debord, J.; Åsberg, A., Pharmacological Research 2018, 130, 316-321, http://doi.org/10.1016/j.phrs.2018.02.016
  2. A donor and recipient candidate gene association study of allograft loss in renal transplant recipients receiving a tacrolimus-based regimen, Woillard, J.-B.; Gatault, P.; Picard, N.; Arnion, H.; Anglicheau, D.; Marquet, P., American Journal of Transplantation: Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2018, 18, 2905-2913, http://doi.org/10.1111/ajt.14894
  3. Comment on « population pharmacokinetics of mycophenolic acid: An update », Woillard, J.-B.; Debord, J.; Marquet, P., Clinical Pharmacokinetics 2018, 57, 1211-1213, http://doi.org/10.1007/s40262-018-0687-9
  4. Angiotensin iv improves subnormothermic machine perfusion preservation of rat liver graft, Tabka, D.; Bejaoui, M.; Javellaud, J.; Achard, J.-M.; Ben Abdennebi, H., Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie 2018, 104, 841-847, http://doi.org/10.1016/j.biopha.2018.02.080
  5. Longterm risk of solid organ de novo malignancies after liver transplantation: A french national study on 11,226 patients, Sérée, O.; Altieri, M.; Guillaume, E.; De Mil, R.; Lobbedez, T.; Robinson, P.; Segol, P.; Salamé, E., et al., Liver Transplantation: Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 2018, 24, 1425-1436, http://doi.org/10.1002/lt.25310
  6. Untargeted screening of urinary peptides using offline nano-liquid chromatography: Maldi-tof/tof mass spectrometry, Sauvage, F.-L.; Passeron, S.; Marquet, P., Methods in Molecular Biology (Clifton, N.J.) 2018, 1788, 113-121, http://doi.org/10.1007/7651_2017_74
  7. A limited sampling strategy to estimate exposure of everolimus in whole blood and peripheral blood mononuclear cells in renal transplant recipients using population pharmacokinetic modeling and bayesian estimators, Robertsen, I.; Debord, J.; Åsberg, A.; Marquet, P.; Woillard, J.-B., Clinical Pharmacokinetics 2018, 57, 1459-1469, http://doi.org/10.1007/s40262-018-0646-5
  8. Survival time to biopsy-proven acute rejection and tacrolimus adverse drug reactions in pediatric liver transplantation, Riva, N.; Dip, M.; Halac, E.; Cáceres Guido, P.; Woillard, J. B.; Licciardone, N.; Chan, D.; Buendía, J., et al., Therapeutic Drug Monitoring 2018, 40, 401-410, http://doi.org/10.1097/FTD.0000000000000517
  9. Combining (non)linear optical and fluorescence analysis of did to enhance lipid phase recognition, Osella, S.; Di Meo, F.; Murugan, N. A.; Fabre, G.; Ameloot, M.; Trouillas, P.; Knippenberg, S., Journal of Chemical Theory and Computation 2018, 14, 5350-5359, http://doi.org/10.1021/acs.jctc.8b00553
  10. Predictive factors of spontaneous cmv dnaemia clearance in kidney transplantation, Noble, J.; Gatault, P.; Sautenet, B.; Gaudy-Graffin, C.; Beby-Defaux, A.; Thierry, A.; Essig, M.; Halimi, J.-M., et al., Journal of Clinical Virology: The Official Publication of the Pan American Society for Clinical Virology 2018, 99-100, 38-43, http://doi.org/10.1016/j.jcv.2017.12.011
  11. Treatment of voluminous and complicated superficial slow-flow vascular malformations with sirolimus (performus): Protocol for a multicenter phase 2 trial with a randomized observational-phase design, Maruani, A.; Boccara, O.; Bessis, D.; Guibaud, L.; Vabres, P.; Mazereeuw-Hautier, J.; Barbarot, S.; Chiaverini, C., et al., Trials 2018, 19, 340, http://doi.org/10.1186/s13063-018-2725-1
  12. Pharmacokinetic therapeutic drug monitoring of advagraf in more than 500 adult renal transplant patients, using an expert system online, Marquet, P.; Bedu, A.; Monchaud, C.; Saint-Marcoux, F.; Rérolle, J.-P.; Etienne, I.; Kamar, N.; Moulin, B., et al., Therapeutic Drug Monitoring 2018, 40, 285-291, http://doi.org/10.1097/FTD.0000000000000503
  13. Comparative clinical trial of the variability factors of the exposure indices used for the drug monitoring of two tacrolimus formulations in kidney transplant recipients, Marquet, P.; Albano, L.; Woillard, J.-B.; Rostaing, L.; Kamar, N.; Sakarovitch, C.; Gatault, P.; Buchler, M., et al., Pharmacological Research 2018, 129, 84-94, http://doi.org/10.1016/j.phrs.2017.12.005
  14. Development of a standardized real time pcr for torque teno viruses (ttv) viral load detection and quantification: A new tool for immune monitoring, Kulifaj, D.; Durgueil-Lariviere, B.; Meynier, F.; Munteanu, E.; Pichon, N.; Dubé, M.; Joannes, M.; Essig, M., et al., Journal of Clinical Virology: The Official Publication of the Pan American Society for Clinical Virology 2018, 105, 118-127, http://doi.org/10.1016/j.jcv.2018.06.010
  15. Atomistic picture of fluorescent probes with hydrocarbon tails in lipid bilayer membranes: An investigation of selective affinities and fluorescent anisotropies in different environmental phases, Knippenberg, S.; Fabre, G.; Osella, S.; Di Meo, F.; Paloncýová, M.; Ameloot, M.; Trouillas, P., Langmuir: the ACS journal of surfaces and colloids 2018, 34, 9072-9084, http://doi.org/10.1021/acs.langmuir.8b01164
  16. Recipient selection for optimal utilization of discarded grafts in liver transplantation, Giretti, G.; Barbier, L.; Bucur, P.; Marques, F.; Perarnau, J.-M.; Ferrandière, M.; Tellier, A.-C.; Kerouredan, V., et al., Transplantation 2018, 102, 775-782, http://doi.org/10.1097/TP.0000000000002069
  17. Which neovagina reconstruction procedure for women with mayer-rokitansky-küster-hauser syndrome in the uterus transplantation era? Editorial from the french uterus transplantation committee (cetuf) of cngof, Gauthier, T.; Lavoue, V.; Piver, P.; Aubard, Y.; Ayoubi, J. M.; Garbin, O.; Agostini, A.; Collinet, P., et al., Journal of Gynecology Obstetrics and Human Reproduction 2018, 47, 175-176, http://doi.org/10.1016/j.jogoh.2018.01.003
  18. Recurrence of renal cell cancer after renal transplantation in a multicenter french cohort, Cognard, N.; Anglicheau, D.; Gatault, P.; Girerd, S.; Essig, M.; Hurault de Ligny, B.; Le Meur, Y.; Le Roy, F., et al., Transplantation 2018, 102, 860-867, http://doi.org/10.1097/TP.0000000000002009
  19. Structural patterns of the human abcc4/mrp4 exporter in lipid bilayers rationalize clinically observed polymorphisms, Chantemargue, B.; Di Meo, F.; Berka, K.; Picard, N.; Arnion, H.; Essig, M.; Marquet, P.; Otyepka, M., et al., Pharmacological Research 2018, 133, 318-327, http://doi.org/10.1016/j.phrs.2018.02.029
  20. Ischemia/reperfusion-associated tubular cells injury in renal transplantation: Can metabolomics inform about mechanisms and help identify new therapeutic targets?, Barin-Le Guellec, C.; Largeau, B.; Bon, D.; Marquet, P.; Hauet, T., Pharmacological Research 2018, 129, 34-43, http://doi.org/10.1016/j.phrs.2017.12.032
  1. Tacrolimus updated guidelines through poppk modeling: How to benefit more from cyp3a pre-emptive genotyping prior to kidney transplantation, Woillard, J.-B.; Mourad, M.; Neely, M.; Capron, A.; van Schaik, R. H.; van Gelder, T.; Lloberas, N.; Hesselink, D. A., et al., Frontiers in Pharmacology 2017, 8, 358,
  2. Population pharmacokinetics and bayesian estimators for refined dose adjustment of a new tacrolimus formulation in kidney and liver transplant patients, Woillard, J.-B.; Debord, J.; Monchaud, C.; Saint-Marcoux, F.; Marquet, P., Clinical Pharmacokinetics 2017, 56, 1491-1498, http://doi.org/10.1007/s40262-017-0533-5
  3. Pharmacogenetics of immunosuppressants: State of the art and clinical implementation – recommendations from the french national network of pharmacogenetics (rnpgx), Woillard, J.-B.; Chouchana, L.; Picard, N.; Loriot, M.-A.; (RNPGX), F. N. o. P., Therapie 2017, 72, 285-299, http://doi.org/10.1016/j.therap.2016.09.016
  4. Chemoenzymatic preparation and biophysical properties of sulfated quercetin metabolites, Valentová, K.; Káňová, K.; Di Meo, F.; Pelantová, H.; Chambers, C. S.; Rydlová, L.; Petrásková, L.; Křenková, A., et al., International Journal of Molecular Sciences 2017, 18, http://doi.org/10.3390/ijms18112231
  5. Uterus tolerance to extended cold ischemic storage after auto-transplantation in ewes, Tricard, J.; Ponsonnard, S.; Tholance, Y.; Mesturoux, L.; Lachatre, D.; Couquet, C.; Terro, F.; Yardin, C., et al., European Journal of Obstetrics, Gynecology, and Reproductive Biology 2017, 214, 162-167, http://doi.org/10.1016/j.ejogrb.2017.05.013
  6. An adjustable predictive score of graft survival in kidney transplant patients and the levels of risk linked to de novo donor-specific anti-hla antibodies, Prémaud, A.; Filloux, M.; Gatault, P.; Thierry, A.; Büchler, M.; Munteanu, E.; Marquet, P.; Essig, M., et al., PloS One 2017, 12, e0180236, http://doi.org/10.1371/journal.pone.0180236
  7. Influence of cyclosporine and everolimus on the main mycophenolate mofetil pharmacokinetic parameters: Cross-sectional study, Noreikaitė, A.; Saint-Marcoux, F.; Marquet, P.; Kaduševičius, E.; Stankevičius, E., Medicine 2017, 96, e6469, http://doi.org/10.1097/MD.0000000000006469
  8. Activity of the calcineurin pathway in patients on the liver transplantation waiting list: Factors of variability and response to tacrolimus inhibition, Noceti, O.; Pouché, L.; Esperón, P.; Lens, D.; Vital, M.; Touriño, C.; Gerona, S.; Woillard, J.-B., et al., Clinical Chemistry 2017, 63, 1734-1744, http://doi.org/10.1373/clinchem.2017.272534
  9. Impact of lipid composition and photosensitizer hydrophobicity on the efficiency of light-triggered liposomal release, Massiot, J.; Makky, A.; Di Meo, F.; Chapron, D.; Trouillas, P.; Rosilio, V., Physical Chemistry Chemical Physics 2017, 19 (18), 11460-11473, http://doi.org/10.1039/C7CP00983F
  10. Which donor for uterus transplants: Brain-dead donor or living donor? A systematic review, Lavoué, V.; Vigneau, C.; Duros, S.; Boudjema, K.; Levêque, J.; Piver, P.; Aubard, Y.; Gauthier, T., Transplantation 2017, 101, 267-273, http://doi.org/10.1097/TP.0000000000001481
  11. Genome-wide association study of acute renal graft rejection, Ghisdal, L.; Baron, C.; Lebranchu, Y.; Viklický, O.; Konarikova, A.; Naesens, M.; Kuypers, D.; Dinic, M., et al., American Journal of Transplantation: Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2017, 17, 201-209, http://doi.org/10.1111/ajt.13912
  12. Reduction of extended-release tacrolimus dose in low-immunological-risk kidney transplant recipients increases risk of rejection and appearance of donor-specific antibodies: A randomized study, Gatault, P.; Kamar, N.; Büchler, M.; Colosio, C.; Bertrand, D.; Durrbach, A.; Albano, L.; Rivalan, J., et al., American Journal of Transplantation: Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2017, 17, 1370-1379, http://doi.org/10.1111/ajt.14109
  13. Towards therapeutic drug monitoring of everolimus in cancer? Results of an exploratory study of exposure-effect relationship, Deppenweiler, M.; Falkowski, S.; Saint-Marcoux, F.; Monchaud, C.; Picard, N.; Laroche, M.-L.; Tubiana-Mathieu, N.; Venat-Bouvet, L., et al., Pharmacological Research 2017, 121, 138-144, http://doi.org/10.1016/j.phrs.2017.04.029
  14. Unravelling the immunopathological mechanisms of heavy chain deposition disease with implications for clinical management, Bridoux, F.; Javaugue, V.; Bender, S.; Leroy, F.; Aucouturier, P.; Debiais-Delpech, C.; Goujon, J.-M.; Quellard, N., et al., Kidney International 2017, 91, 423-434, http://doi.org/10.1016/j.kint.2016.09.004
  1. Evolution and determinants of health-related quality-of-life in kidney transplant patients over the first 3 years after transplantation, Villeneuve, C.; Laroche, M.-L.; Essig, M.; Merville, P.; Kamar, N.; Coubret, A.; Lacroix, I.; Bouchet, S., et al., Transplantation 2016, 100, 640-647, http://doi.org/10.1097/TP.0000000000000846
  2. Minimization of maintenance immunosuppressive therapy after renal transplantation comparing cyclosporine a/azathioprine or cyclosporine a/mycophenolate mofetil bitherapy to cyclosporine a monotherapy: A 10-year postrandomization follow-up study, Thierry, A.; Le Meur, Y.; Ecotière, L.; Abou-Ayache, R.; Etienne, I.; Laurent, C.; Vuiblet, V.; Colosio, C., et al., Transplant International: Official Journal of the European Society for Organ Transplantation 2016, 29, 23-33, http://doi.org/10.1111/tri.12627
  3. Mycophenolic acid pharmacokinetics and relapse in children with steroid-dependent idiopathic nephrotic syndrome, Tellier, S.; Dallocchio, A.; Guigonis, V.; Saint-Marcoux, F.; Llanas, B.; Ichay, L.; Bandin, F.; Godron, A., et al., Clinical journal of the American Society of Nephrology: CJASN 2016, 11, 1777-1782, http://doi.org/10.2215/CJN.00320116
  4. Genetic polymorphisms in the immune response: A focus on kidney transplantation, Stojanova, J.; Pouché, L.; Picard, N., Clinical Biochemistry 2016, 49, 363-376, http://doi.org/10.1016/j.clinbiochem.2015.07.016
  5. Analytical aspects of the implementation of biomarkers in clinical transplantation, Shipkova, M.; López, O. M.; Picard, N.; Noceti, O.; Sommerer, C.; Christians, U.; Wieland, E., Therapeutic Drug Monitoring 2016, 38 Suppl 1, S80-92, http://doi.org/10.1097/FTD.0000000000000230
  6. Therapeutic drug monitoring of everolimus: A consensus report, Shipkova, M.; Hesselink, D. A.; Holt, D. W.; Billaud, E. M.; van Gelder, T.; Kunicki, P. K.; Brunet, M.; Budde, K., et al., Therapeutic Drug Monitoring 2016, 38, 143-169, http://doi.org/10.1097/FTD.0000000000000260
  7. Assuring the proper analytical performance of measurement procedures for immunosuppressive drug concentrations in clinical practice: Recommendations of the international association of therapeutic drug monitoring and clinical toxicology immunosuppressive drug scientific committee, Seger, C.; Shipkova, M.; Christians, U.; Billaud, E. M.; Wang, P.; Holt, D. W.; Brunet, M.; Kunicki, P. K., et al., Therapeutic Drug Monitoring 2016, 38, 170-189, http://doi.org/10.1097/FTD.0000000000000269
  8. Corticosteroid-sparing and optimization of mycophenolic acid exposure in liver transplant recipients receiving mycophenolate mofetil and tacrolimus: A randomized, multicenter study, Saliba, F.; Rostaing, L.; Gugenheim, J.; Durand, F.; Radenne, S.; Leroy, V.; Neau-Cransac, M.; Calmus, Y., et al., Transplantation 2016, 100, 1705-1713, http://doi.org/10.1097/TP.0000000000001228
  9. New challenges and promises in solid organ transplantation pharmacogenetics: The genetic variability of proteins involved in the pharmacodynamics of immunosuppressive drugs, Pouché, L.; Stojanova, J.; Marquet, P.; Picard, N., Pharmacogenomics 2016, 17, 277-296, http://doi.org/10.2217/pgs.15.169
  10. A candidate gene approach of the calcineurin pathway to identify variants associated with clinical outcomes in renal transplantation, Pouché, L.; Koitka, M.; Stojanova, J.; Woillard, J.-B.; Monchaud, C.; Villeneuve, C.; Essig, M.; Abraham, J., et al., Pharmacogenomics 2016, 17, 375-391, http://doi.org/10.2217/pgs.15.181
  11. Pharmacogenetic biomarkers predictive of the pharmacokinetics and pharmacodynamics of immunosuppressive drugs, Picard, N.; Bergan, S.; Marquet, P.; van Gelder, T.; Wallemacq, P.; Hesselink, D. A.; Haufroid, V., Therapeutic Drug Monitoring 2016, 38 Suppl 1, S57-69, http://doi.org/10.1097/FTD.0000000000000255
  12. Uterus transplantation in france: For which patients?, Huet, S.; Tardieu, A.; Filloux, M.; Essig, M.; Pichon, N.; Therme, J. F.; Piver, P.; Aubard, Y., et al., European Journal of Obstetrics, Gynecology, and Reproductive Biology 2016, 205, 7-10, http://doi.org/10.1016/j.ejogrb.2016.08.027
  13. Uterus human leucocyte antigen expression in the perspective of transplantation, Gauthier, T.; Filloux, M.; Guillaudeau, A.; Essig, M.; Bibes, R.; Pacha, A. F.; Piver, P.; Aubard, Y., et al., The Journal of Obstetrics and Gynaecology Research 2016, 42, 1789-1795, http://doi.org/10.1111/jog.13107
  14. Contribution of next generation sequencing to early detection of cytomegalovirus ul97 emerging mutants and viral subpopulations analysis in kidney transplant recipients, Garrigue, I.; Moulinas, R.; Recordon-Pinson, P.; Delacour, M.-L.; Essig, M.; Kaminski, H.; Rerolle, J.-P.; Merville, P., et al., Journal of Clinical Virology: The Official Publication of the Pan American Society for Clinical Virology 2016, 80, 74-81, http://doi.org/10.1016/j.jcv.2016.04.017
  15. In silico pharmacology: Drug membrane partitioning and crossing, Di Meo, F.; Fabre, G.; Berka, K.; Ossman, T.; Chantemargue, B.; Paloncýová, M.; Marquet, P.; Otyepka, M., et al., Pharmacological Research 2016, 111, 471-486, http://doi.org/10.1016/j.phrs.2016.06.030
  16. Influence of donor and recipient cyp3a4, cyp3a5, and abcb1 genotypes on clinical outcomes and nephrotoxicity in liver transplant recipients, Debette-Gratien, M.; Woillard, J.-B.; Picard, N.; Sebagh, M.; Loustaud-Ratti, V.; Sautereau, D.; Samuel, D.; Marquet, P., Transplantation 2016, 100, 2129-2137, http://doi.org/10.1097/TP.0000000000001394
  17. The propkd score: A new algorithm to predict renal survival in autosomal dominant polycystic kidney disease, Cornec-Le Gall, E.; Audrézet, M.-P.; Rousseau, A.; Hourmant, M.; Renaudineau, E.; Charasse, C.; Morin, M.-P.; Moal, M.-C., et al., Journal of the American Society of Nephrology: JASN 2016, 27, 942-951, http://doi.org/10.1681/ASN.2015010016
  18. Advagraf(®) , a once-daily prolonged release tacrolimus formulation, in kidney transplantation: Literature review and guidelines from a panel of experts, Caillard, S.; Moulin, B.; Buron, F.; Mariat, C.; Audard, V.; Grimbert, P.; Marquet, P., Transplant International: Official Journal of the European Society for Organ Transplantation 2016, 29, 860-869, http://doi.org/10.1111/tri.12674
  19. Barcelona consensus on biomarker-based immunosuppressive drugs management in solid organ transplantation, Brunet, M.; Shipkova, M.; van Gelder, T.; Wieland, E.; Sommerer, C.; Budde, K.; Haufroid, V.; Christians, U., et al., Therapeutic Drug Monitoring 2016, 38 Suppl 1, S1-20, http://doi.org/10.1097/FTD.0000000000000287
  20. Plasma and intracellular exposure to ganciclovir in adult renal transplant recipients: Is there an association with haematological toxicity?, Billat, P.-A.; Woillard, J.-B.; Essig, M.; Sauvage, F.-L.; Picard, N.; Alain, S.; Neely, M.; Marquet, P., et al., The Journal of Antimicrobial Chemotherapy 2016, 71, 484-489, http://doi.org/10.1093/jac/dkv342
  21. Multidrug resistance-associated protein 4 (mrp4) controls ganciclovir intracellular accumulation and contributes to ganciclovir-induced neutropenia in renal transplant patients, Billat, P.-A.; Ossman, T.; Saint-Marcoux, F.; Essig, M.; Rerolle, J.-P.; Kamar, N.; Rostaing, L.; Kaminski, H., et al., Pharmacological Research 2016, 111, 501-508, http://doi.org/10.1016/j.phrs.2016.07.012
  22. Validation of the psychometrics properties of a french quality of life questionnaire among a cohort of renal transplant recipients less than one year, Beauger, D.; Fruit, D.; Villeneuve, C.; Laroche, M.-L.; Jouve, E.; Rousseau, A.; Boyer, L.; Gentile, S., Quality of Life Research: An International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation 2016, 25, 2347-2359, http://doi.org/10.1007/s11136-016-1271-0
  23. A blue-light-emitting bodipy probe for lipid membranes, Bacalum, M.; Wang, L.; Boodts, S.; Yuan, P.; Leen, V.; Smisdom, N.; Fron, E.; Knippenberg, S., et al., Langmuir: the ACS journal of surfaces and colloids 2016, 32, 3495-3505, http://doi.org/10.1021/acs.langmuir.6b00478
  24. Establishing biomarkers in transplant medicine: A critical review of current approaches, Anglicheau, D.; Naesens, M.; Essig, M.; Gwinner, W.; Marquet, P., Transplantation 2016, 100, 2024-2038, http://doi.org/10.1097/TP.0000000000001321
  1. Mycophenolic mofetil optimized pharmacokinetic modelling, and exposure-effect associations in adult heart transplant recipients, Woillard, J.-B.; Saint-Marcoux, F.; Monchaud, C.; Youdarène, R.; Pouche, L.; Marquet, P., Pharmacological Research 2015, 99, 308-315, http://doi.org/10.1016/j.phrs.2015.07.012
  2. How to handle missed or delayed doses of tacrolimus in renal transplant recipients? A pharmacokinetic investigation, Saint-Marcoux, F.; Woillard, J.-B.; Monchaud, C.; Friedl, J.; Bocquentin, F.; Essig, M.; Marquet, P., Pharmacological Research 2015, 100, 281-287, http://doi.org/10.1016/j.phrs.2015.08.020
  3. Controlled attenuation parameter and liver stiffness measurements for steatosis assessment in the liver transplant of brain dead donors, Mancia, C.; Loustaud-Ratti, V.; Carrier, P.; Naudet, F.; Bellissant, E.; Labrousse, F.; Pichon, N., Transplantation 2015, 99, 1619-1624, http://doi.org/10.1097/TP.0000000000000652
  4. Uterine transplantation: Is there a real demand?, Gauthier, T.; Garnault, D.; Therme, J.-F.; Piver, P.; Essig, M.; Pichon, N.; Marquet, P.; Aubard, Y., Gynecologie, Obstetrique & Fertilite 2015, 43, 133-138, http://doi.org/10.1016/j.gyobfe.2014.12.005
  5. Lipocarbazole, an efficient lipid peroxidation inhibitor anchored in the membrane, Fabre, G.; Hänchen, A.; Calliste, C.-A.; Berka, K.; Banala, S.; Otyepka, M.; Süssmuth, R. D.; Trouillas, P., Bioorganic & Medicinal Chemistry 2015, 23, 4866-4870, http://doi.org/10.1016/j.bmc.2015.05.031
  6. Synergism of antioxidant action of vitamins e, c and quercetin is related to formation of molecular associations in biomembranes, Fabre, G.; Bayach, I.; Berka, K.; Paloncýová, M.; Starok, M.; Rossi, C.; Duroux, J.-L.; Otyepka, M., et al., Chemical Communications (Cambridge, England) 2015, 51, 7713-7716, http://doi.org/10.1039/c5cc00636h
  7. Bronchiectasis diagnosed after renal transplantation: A retrospective multicenter study, Dury, S.; Colosio, C.; Etienne, I.; Anglicheau, D.; Merieau, E.; Caillard, S.; Rivalan, J.; Thervet, E., et al., BMC pulmonary medicine 2015, 15, 141, http://doi.org/10.1186/s12890-015-0133-9
  8. Personalized adapted physical activity before liver transplantation: Acceptability and results, Debette-Gratien, M.; Tabouret, T.; Antonini, M.-T.; Dalmay, F.; Carrier, P.; Legros, R.; Jacques, J.; Vincent, F., et al., Transplantation 2015, 99, 145-150, http://doi.org/10.1097/TP.0000000000000245
  9. Impact of laboratory practices on interlaboratory variability in therapeutic drug monitoring of immunosuppressive drugs, Christians, U.; Vinks, A. A.; Langman, L. J.; Clarke, W.; Wallemacq, P.; van Gelder, T.; Renjen, V.; Marquet, P., et al., Therapeutic Drug Monitoring 2015, 37, 718-724, http://doi.org/10.1097/FTD.0000000000000205
  10. Liquid chromatography tandem mass spectrometry quantitation of intracellular concentrations of ganciclovir and its phosphorylated forms, Billat, P.-A.; Sauvage, F.-L.; Picard, N.; Tafzi, N.; Alain, S.; Essig, M.; Marquet, P.; Saint-Marcoux, F., Analytical and Bioanalytical Chemistry 2015, 407, 3449-3456, http://doi.org/10.1007/s00216-015-8554-0